CNBC
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Thursday, August 6, 2026
Eli Lilly reported stronger financial results and market position in obesity treatments compared to Novo Nordisk in their latest earnings. Novo Nordisk is working to regain market share in the obesity drug segment. Both companies compete in the same therapeutic market.
Original reporting: https://www.cnbc.com/2026/08/06/eli-lilly-novo-nordisk-earnings-glp1-market.html